3 Beaten-Down Growth Stocks With More Than 50% Upside Potential_老虎社区_美港股上老虎

3 Beaten-Down Growth Stocks With More Than 50% Upside Potential

investorplace2022-02-26

Following the stock market bottom in Mar. 2020, growth stocks dominated the list of best-performing stocks for the first year of the new bull market. Since then, growth stocks have been mired in a ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Akyy12
·2022-02-27
Pls like
回复
1
举报
bobbylim
·2022-02-27
Hmm
回复
点赞
举报
生肉麵加豬油渣
·2022-02-26
abundance e of beaten down stocks...
回复
2
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1191113671?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2022-02-26 07:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191113671","market":"us","top_or_hot":-1,"title":"3 Beaten-Down Growth Stocks With More Than 50% Upside Potential","media":"investorplace","content":"<div>\n<p>Following the stock market bottom in Mar. 2020, growth stocks dominated the list of best-performing stocks for the first year of the new bull market. Since then, growth stocks have been mired in a ...</p>\n\n<a href=\"https://investorplace.com/2022/02/3-beaten-down-growth-stocks-with-more-than-50-upside-potential/\">网页链接</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks With More Than 50% Upside Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks With More Than 50% Upside Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-26 07:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/02/3-beaten-down-growth-stocks-with-more-than-50-upside-potential/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Following the stock market bottom in Mar. 2020, growth stocks dominated the list of best-performing stocks for the first year of the new bull market. Since then, growth stocks have been mired in a ...</p>\n\n<a href=\"https://investorplace.com/2022/02/3-beaten-down-growth-stocks-with-more-than-50-upside-potential/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VEEV","symbol_name":"Veeva Systems Inc.","start_time":0,"source_url":"https://investorplace.com/2022/02/3-beaten-down-growth-stocks-with-more-than-50-upside-potential/","article_id":"1191113671","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191113671","pubTimestamp":1645832617,"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"Following the stock market bottom in Mar. 2020, growth stocks dominated the list of best-performing ","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"VEEV":"Veeva Systems Inc.","ZTS":"Zoetis Inc.","RMD":"瑞思迈"},"translate_title":"3只上涨潜力超过50%的跌跌不休成长股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD":0.9,"VEEV":0.9,"ZTS":0.9},"content_text":"Following the stock market bottom in Mar. 2020, growth stocks dominated the list of best-performing stocks for the first year of the new bull market. Since then, growth stocks have been mired in a brutal bear market. There is no better example of this than Cathie Wood’s Ark Innovation ETF (NYSEARCA:ARKK), which had a 391% gain from Mar. 2020 to its high in Feb. 2021. Since then, ARKK has given back most of these gains and is down 60% from these lofty levels.The major factor behind this sharp decline is increasing inflationary pressures, resulting in expectations that the U.S. Federal Reserve will hike rates seven times this year. Rising inflation and interest rates are bearish for growth stocks because it makes their future cash flows less valuable. However, we also know that oversold markets also create an opportunity to buy high-quality stocks at a discount.The key is to look for companies whose earnings momentum and growth are unaffected by changes in economic or monetary conditions. Therefore, investors should consider the following 3 high-quality growth stocks:Veeva Systems (NYSE:VEEV)Resmed, Inc. (NYSE:RMD)Zoetis (NYSE:ZTS)Growth Stocks: Veeva Systems (VEEV)Veeva Systems is a cloud computing and enterprise software company for the healthcare, pharmaceutical, and life sciences industries. It provides software solutions for the unique needs of companies in these industries, from meeting regulatory standards to conducting clinical trials to managing operations.Thus, it is positioned at the intersection of two booming trends — healthcare and cloud computing — which show no signs of exhaustion. These industries have produced some of the biggest stock market winners in recent history.The healthcare sector’s growth is fueled by demographics due to an aging population in developed countries globally, increased government spending, and the constant stream of innovations that lead to new treatments. Healthcare spending as a share of gross domestic product has risen to 18% in 2020 from under 12% in 1990.Veeva combines the growth and high margins of a cloud computing company with the attractive economics of the healthcare industry that has high switching costs and wide moats, leading to high rates of recurring revenue.These positives are reflected in Veeva’s last earnings report which shows a 26% increase in revenue and a 28% jump in operating income. Next quarter, analysts expect 13% earnings growth. This combination of earnings growth and stock price deflation has resulted in valuations becoming quite attractive, especially considering that it has profit margins that are more than double that of the S&P 500 and expectations of double-digit earnings growth over the next five years.Thus, it is not surprising that VEEV has an overall B rating, which translates to a Buy in our POWR Ratings system. It also has an A for Quality. It is one of the leading stocks in a large total addressable market with only a handful of competitors. Additionally, VEEV has a B for growth. This makes sense given its intersection of two large and growing markets — healthcare and cloud computing. Click here to see more of VEEV’s POWR Ratings, including grades for Value, Momentum, and Stability.Resmed, Inc. (RMD)RMD develops, manufactures, distributes, and markets medical devices and software applications for the healthcare market. The company operates in two segments: Sleep and Respiratory Care, and Software as a Service.RMD provides treatments for issues like sleep apnea with its CPAP devices and masks, as well as devices for obstructive pulmonary disease, neuromuscular disease, and other respiratory-related conditions. Unfortunately, due to rising rates of chronic health issues like diabetes and obesity, the demand for RMD’s products is only growing.This makes RMD a high-quality growth stock as its long-term prospects are disconnected from short-term issues like economic growth rates or monetary policy. Instead, RMD is serving a growing market with products that are essential for improving quality of life. Due to their nature, these products also have high margins and rates of recurring revenue.We can see this momentum in its recent earnings report, which showed revenues increasing by 12% and net income increasing by 5%. Next year, analysts forecast revenue growth and earnings per share (EPS) growth of 17% and 15%, respectively.RMD is also a standout in terms of the POWR Ratings with an overall B rating, translating to a Buy. The POWR Ratings assess stocks by 118 distinct factors, each with its own weighting.RMD has strong ratings across the board, including a B grade for Growth as analysts are forecasting double-digit revenue growth over the next decade. Within the Medical – Devices & Equipment industry, RMD is ranked #33 out of 165 stocks. Click here to see RMD’s complete POWR Ratings.Growth Stocks: Zoetis (ZTS)Zoetis was spun off from Pfizer (NYSE:PFE) in 2013 and is now the leading manufacturer and producer of animal health products including medicines, vaccines, and diagnostic products. Since its debut, the stock is up more than six-fold.One major factor in Zoeitis’ growth is that pet ownership is on the rise. Spending on pets is also rising. These trends have been in place for decades and are likely to persist, creating a positive tailwind for animal health companies like ZTS. Additionally, more people are choosing to buy health insurance for their pets, as well.The weakness in growth stocks has led to ZTS’ price pulling back by 30%. However, its recent earnings report shows that the company continues to have strong momentum. The company reported an 11% increase in revenue and 14% increase in earnings. For the full year, analysts forecast 16% revenue growth and 21% EPS growth.Given these factors, it is not surprising that ZTS has a B rating, which equates to a Buy in our proprietary rating system. B-rated stocks have posted an average annual performance of 21.1% which compares favorably to the S&P 500’s average gain of 8%.In terms of component grades, ZTS has an A for Quality and a B for Stability. ZTS is one of the leading companies in a growing sector. It also is returning cash to shareholders via its dividend and through share buybacks. Click here to get more information about ZTS’ POWR Ratings.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":636594879,"gmtCreate":1645977565640,"gmtModify":1645977565713,"author":{"id":"4098595137500940","authorId":"4098595137500940","name":"Akyy12","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/636594879","repostId":1191113671,"repostType":4,"repost":{"id":"1191113671","pubTimestamp":1645832617,"share":"https://www.laohu8.com/m/news/1191113671?lang=&edition=full","pubTime":"2022-02-26 07:43","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks With More Than 50% Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1191113671","media":"investorplace","summary":"Following the stock market bottom in Mar. 2020, growth stocks dominated the list of best-performing ","content":"<html><head></head><body><p>Following the stock market bottom in Mar. 2020, growth stocks dominated the list of best-performing stocks for the first year of the new bull market. Since then, growth stocks have been mired in a brutal bear market. There is no better example of this than Cathie Wood’s Ark Innovation ETF (NYSEARCA:ARKK), which had a 391% gain from Mar. 2020 to its high in Feb. 2021. Since then, ARKK has given back most of these gains and is down 60% from these lofty levels.</p><p>The major factor behind this sharp decline is increasing inflationary pressures, resulting in expectations that the U.S. Federal Reserve will hike rates seven times this year. Rising inflation and interest rates are bearish for growth stocks because it makes their future cash flows less valuable. However, we also know that oversold markets also create an opportunity to buy high-quality stocks at a discount.</p><p>The key is to look for companies whose earnings momentum and growth are unaffected by changes in economic or monetary conditions. Therefore, investors should consider the following 3 high-quality growth stocks:</p><p>Veeva Systems (NYSE:VEEV)</p><p>Resmed, Inc. (NYSE:RMD)</p><p>Zoetis (NYSE:ZTS)</p><h2>Growth Stocks: Veeva Systems (VEEV)</h2><p>Veeva Systems is a cloud computing and enterprise software company for the healthcare, pharmaceutical, and life sciences industries. It provides software solutions for the unique needs of companies in these industries, from meeting regulatory standards to conducting clinical trials to managing operations.</p><p>Thus, it is positioned at the intersection of two booming trends — healthcare and cloud computing — which show no signs of exhaustion. These industries have produced some of the biggest stock market winners in recent history.</p><p>The healthcare sector’s growth is fueled by demographics due to an aging population in developed countries globally, increased government spending, and the constant stream of innovations that lead to new treatments. Healthcare spending as a share of gross domestic product has risen to 18% in 2020 from under 12% in 1990.</p><p>Veeva combines the growth and high margins of a cloud computing company with the attractive economics of the healthcare industry that has high switching costs and wide moats, leading to high rates of recurring revenue.</p><p>These positives are reflected in Veeva’s last earnings report which shows a 26% increase in revenue and a 28% jump in operating income. Next quarter, analysts expect 13% earnings growth. This combination of earnings growth and stock price deflation has resulted in valuations becoming quite attractive, especially considering that it has profit margins that are more than double that of the S&amp;P 500 and expectations of double-digit earnings growth over the next five years.</p><p>Thus, it is not surprising that VEEV has an overall B rating, which translates to a Buy in our POWR Ratings system. It also has an A for Quality. It is one of the leading stocks in a large total addressable market with only a handful of competitors. Additionally, VEEV has a B for growth. This makes sense given its intersection of two large and growing markets — healthcare and cloud computing. Click here to see more of VEEV’s POWR Ratings, including grades for Value, Momentum, and Stability.</p><h2>Resmed, Inc. (RMD)</h2><p>RMD develops, manufactures, distributes, and markets medical devices and software applications for the healthcare market. The company operates in two segments: Sleep and Respiratory Care, and Software as a Service.</p><p>RMD provides treatments for issues like sleep apnea with its CPAP devices and masks, as well as devices for obstructive pulmonary disease, neuromuscular disease, and other respiratory-related conditions. Unfortunately, due to rising rates of chronic health issues like diabetes and obesity, the demand for RMD’s products is only growing.</p><p>This makes RMD a high-quality growth stock as its long-term prospects are disconnected from short-term issues like economic growth rates or monetary policy. Instead, RMD is serving a growing market with products that are essential for improving quality of life. Due to their nature, these products also have high margins and rates of recurring revenue.</p><p>We can see this momentum in its recent earnings report, which showed revenues increasing by 12% and net income increasing by 5%. Next year, analysts forecast revenue growth and earnings per share (EPS) growth of 17% and 15%, respectively.</p><p>RMD is also a standout in terms of the POWR Ratings with an overall B rating, translating to a Buy. The POWR Ratings assess stocks by 118 distinct factors, each with its own weighting.</p><p>RMD has strong ratings across the board, including a B grade for Growth as analysts are forecasting double-digit revenue growth over the next decade. Within the Medical – Devices &amp; Equipment industry, RMD is ranked #33 out of 165 stocks. Click here to see RMD’s complete POWR Ratings.</p><h2>Growth Stocks: Zoetis (ZTS)</h2><p>Zoetis was spun off from Pfizer (NYSE:PFE) in 2013 and is now the leading manufacturer and producer of animal health products including medicines, vaccines, and diagnostic products. Since its debut, the stock is up more than six-fold.</p><p>One major factor in Zoeitis’ growth is that pet ownership is on the rise. Spending on pets is also rising. These trends have been in place for decades and are likely to persist, creating a positive tailwind for animal health companies like ZTS. Additionally, more people are choosing to buy health insurance for their pets, as well.</p><p>The weakness in growth stocks has led to ZTS’ price pulling back by 30%. However, its recent earnings report shows that the company continues to have strong momentum. The company reported an 11% increase in revenue and 14% increase in earnings. For the full year, analysts forecast 16% revenue growth and 21% EPS growth.</p><p>Given these factors, it is not surprising that ZTS has a B rating, which equates to a Buy in our proprietary rating system. B-rated stocks have posted an average annual performance of 21.1% which compares favorably to the S&amp;P 500’s average gain of 8%.</p><p>In terms of component grades, ZTS has an A for Quality and a B for Stability. ZTS is one of the leading companies in a growing sector. It also is returning cash to shareholders via its dividend and through share buybacks. Click here to get more information about ZTS’ POWR Ratings.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks With More Than 50% Upside Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks With More Than 50% Upside Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-26 07:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/02/3-beaten-down-growth-stocks-with-more-than-50-upside-potential/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Following the stock market bottom in Mar. 2020, growth stocks dominated the list of best-performing stocks for the first year of the new bull market. Since then, growth stocks have been mired in a ...</p>\n\n<a href=\"https://investorplace.com/2022/02/3-beaten-down-growth-stocks-with-more-than-50-upside-potential/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZTS":"Zoetis Inc.","VEEV":"Veeva Systems Inc.","RMD":"瑞思迈"},"source_url":"https://investorplace.com/2022/02/3-beaten-down-growth-stocks-with-more-than-50-upside-potential/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191113671","content_text":"Following the stock market bottom in Mar. 2020, growth stocks dominated the list of best-performing stocks for the first year of the new bull market. Since then, growth stocks have been mired in a brutal bear market. There is no better example of this than Cathie Wood’s Ark Innovation ETF (NYSEARCA:ARKK), which had a 391% gain from Mar. 2020 to its high in Feb. 2021. Since then, ARKK has given back most of these gains and is down 60% from these lofty levels.The major factor behind this sharp decline is increasing inflationary pressures, resulting in expectations that the U.S. Federal Reserve will hike rates seven times this year. Rising inflation and interest rates are bearish for growth stocks because it makes their future cash flows less valuable. However, we also know that oversold markets also create an opportunity to buy high-quality stocks at a discount.The key is to look for companies whose earnings momentum and growth are unaffected by changes in economic or monetary conditions. Therefore, investors should consider the following 3 high-quality growth stocks:Veeva Systems (NYSE:VEEV)Resmed, Inc. (NYSE:RMD)Zoetis (NYSE:ZTS)Growth Stocks: Veeva Systems (VEEV)Veeva Systems is a cloud computing and enterprise software company for the healthcare, pharmaceutical, and life sciences industries. It provides software solutions for the unique needs of companies in these industries, from meeting regulatory standards to conducting clinical trials to managing operations.Thus, it is positioned at the intersection of two booming trends — healthcare and cloud computing — which show no signs of exhaustion. These industries have produced some of the biggest stock market winners in recent history.The healthcare sector’s growth is fueled by demographics due to an aging population in developed countries globally, increased government spending, and the constant stream of innovations that lead to new treatments. Healthcare spending as a share of gross domestic product has risen to 18% in 2020 from under 12% in 1990.Veeva combines the growth and high margins of a cloud computing company with the attractive economics of the healthcare industry that has high switching costs and wide moats, leading to high rates of recurring revenue.These positives are reflected in Veeva’s last earnings report which shows a 26% increase in revenue and a 28% jump in operating income. Next quarter, analysts expect 13% earnings growth. This combination of earnings growth and stock price deflation has resulted in valuations becoming quite attractive, especially considering that it has profit margins that are more than double that of the S&P 500 and expectations of double-digit earnings growth over the next five years.Thus, it is not surprising that VEEV has an overall B rating, which translates to a Buy in our POWR Ratings system. It also has an A for Quality. It is one of the leading stocks in a large total addressable market with only a handful of competitors. Additionally, VEEV has a B for growth. This makes sense given its intersection of two large and growing markets — healthcare and cloud computing. Click here to see more of VEEV’s POWR Ratings, including grades for Value, Momentum, and Stability.Resmed, Inc. (RMD)RMD develops, manufactures, distributes, and markets medical devices and software applications for the healthcare market. The company operates in two segments: Sleep and Respiratory Care, and Software as a Service.RMD provides treatments for issues like sleep apnea with its CPAP devices and masks, as well as devices for obstructive pulmonary disease, neuromuscular disease, and other respiratory-related conditions. Unfortunately, due to rising rates of chronic health issues like diabetes and obesity, the demand for RMD’s products is only growing.This makes RMD a high-quality growth stock as its long-term prospects are disconnected from short-term issues like economic growth rates or monetary policy. Instead, RMD is serving a growing market with products that are essential for improving quality of life. Due to their nature, these products also have high margins and rates of recurring revenue.We can see this momentum in its recent earnings report, which showed revenues increasing by 12% and net income increasing by 5%. Next year, analysts forecast revenue growth and earnings per share (EPS) growth of 17% and 15%, respectively.RMD is also a standout in terms of the POWR Ratings with an overall B rating, translating to a Buy. The POWR Ratings assess stocks by 118 distinct factors, each with its own weighting.RMD has strong ratings across the board, including a B grade for Growth as analysts are forecasting double-digit revenue growth over the next decade. Within the Medical – Devices & Equipment industry, RMD is ranked #33 out of 165 stocks. Click here to see RMD’s complete POWR Ratings.Growth Stocks: Zoetis (ZTS)Zoetis was spun off from Pfizer (NYSE:PFE) in 2013 and is now the leading manufacturer and producer of animal health products including medicines, vaccines, and diagnostic products. Since its debut, the stock is up more than six-fold.One major factor in Zoeitis’ growth is that pet ownership is on the rise. Spending on pets is also rising. These trends have been in place for decades and are likely to persist, creating a positive tailwind for animal health companies like ZTS. Additionally, more people are choosing to buy health insurance for their pets, as well.The weakness in growth stocks has led to ZTS’ price pulling back by 30%. However, its recent earnings report shows that the company continues to have strong momentum. The company reported an 11% increase in revenue and 14% increase in earnings. For the full year, analysts forecast 16% revenue growth and 21% EPS growth.Given these factors, it is not surprising that ZTS has a B rating, which equates to a Buy in our proprietary rating system. B-rated stocks have posted an average annual performance of 21.1% which compares favorably to the S&P 500’s average gain of 8%.In terms of component grades, ZTS has an A for Quality and a B for Stability. ZTS is one of the leading companies in a growing sector. It also is returning cash to shareholders via its dividend and through share buybacks. Click here to get more information about ZTS’ POWR Ratings.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":636500050,"gmtCreate":1645954258418,"gmtModify":1645954258604,"author":{"id":"3575499385722971","authorId":"3575499385722971","name":"bobbylim","avatar":"https://static.tigerbbs.com/1d9753dcafa04623c0e98c0bcaa291ae","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/636500050","repostId":1191113671,"repostType":4,"repost":{"id":"1191113671","pubTimestamp":1645832617,"share":"https://www.laohu8.com/m/news/1191113671?lang=&edition=full","pubTime":"2022-02-26 07:43","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks With More Than 50% Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1191113671","media":"investorplace","summary":"Following the stock market bottom in Mar. 2020, growth stocks dominated the list of best-performing ","content":"<html><head></head><body><p>Following the stock market bottom in Mar. 2020, growth stocks dominated the list of best-performing stocks for the first year of the new bull market. Since then, growth stocks have been mired in a brutal bear market. There is no better example of this than Cathie Wood’s Ark Innovation ETF (NYSEARCA:ARKK), which had a 391% gain from Mar. 2020 to its high in Feb. 2021. Since then, ARKK has given back most of these gains and is down 60% from these lofty levels.</p><p>The major factor behind this sharp decline is increasing inflationary pressures, resulting in expectations that the U.S. Federal Reserve will hike rates seven times this year. Rising inflation and interest rates are bearish for growth stocks because it makes their future cash flows less valuable. However, we also know that oversold markets also create an opportunity to buy high-quality stocks at a discount.</p><p>The key is to look for companies whose earnings momentum and growth are unaffected by changes in economic or monetary conditions. Therefore, investors should consider the following 3 high-quality growth stocks:</p><p>Veeva Systems (NYSE:VEEV)</p><p>Resmed, Inc. (NYSE:RMD)</p><p>Zoetis (NYSE:ZTS)</p><h2>Growth Stocks: Veeva Systems (VEEV)</h2><p>Veeva Systems is a cloud computing and enterprise software company for the healthcare, pharmaceutical, and life sciences industries. It provides software solutions for the unique needs of companies in these industries, from meeting regulatory standards to conducting clinical trials to managing operations.</p><p>Thus, it is positioned at the intersection of two booming trends — healthcare and cloud computing — which show no signs of exhaustion. These industries have produced some of the biggest stock market winners in recent history.</p><p>The healthcare sector’s growth is fueled by demographics due to an aging population in developed countries globally, increased government spending, and the constant stream of innovations that lead to new treatments. Healthcare spending as a share of gross domestic product has risen to 18% in 2020 from under 12% in 1990.</p><p>Veeva combines the growth and high margins of a cloud computing company with the attractive economics of the healthcare industry that has high switching costs and wide moats, leading to high rates of recurring revenue.</p><p>These positives are reflected in Veeva’s last earnings report which shows a 26% increase in revenue and a 28% jump in operating income. Next quarter, analysts expect 13% earnings growth. This combination of earnings growth and stock price deflation has resulted in valuations becoming quite attractive, especially considering that it has profit margins that are more than double that of the S&amp;P 500 and expectations of double-digit earnings growth over the next five years.</p><p>Thus, it is not surprising that VEEV has an overall B rating, which translates to a Buy in our POWR Ratings system. It also has an A for Quality. It is one of the leading stocks in a large total addressable market with only a handful of competitors. Additionally, VEEV has a B for growth. This makes sense given its intersection of two large and growing markets — healthcare and cloud computing. Click here to see more of VEEV’s POWR Ratings, including grades for Value, Momentum, and Stability.</p><h2>Resmed, Inc. (RMD)</h2><p>RMD develops, manufactures, distributes, and markets medical devices and software applications for the healthcare market. The company operates in two segments: Sleep and Respiratory Care, and Software as a Service.</p><p>RMD provides treatments for issues like sleep apnea with its CPAP devices and masks, as well as devices for obstructive pulmonary disease, neuromuscular disease, and other respiratory-related conditions. Unfortunately, due to rising rates of chronic health issues like diabetes and obesity, the demand for RMD’s products is only growing.</p><p>This makes RMD a high-quality growth stock as its long-term prospects are disconnected from short-term issues like economic growth rates or monetary policy. Instead, RMD is serving a growing market with products that are essential for improving quality of life. Due to their nature, these products also have high margins and rates of recurring revenue.</p><p>We can see this momentum in its recent earnings report, which showed revenues increasing by 12% and net income increasing by 5%. Next year, analysts forecast revenue growth and earnings per share (EPS) growth of 17% and 15%, respectively.</p><p>RMD is also a standout in terms of the POWR Ratings with an overall B rating, translating to a Buy. The POWR Ratings assess stocks by 118 distinct factors, each with its own weighting.</p><p>RMD has strong ratings across the board, including a B grade for Growth as analysts are forecasting double-digit revenue growth over the next decade. Within the Medical – Devices &amp; Equipment industry, RMD is ranked #33 out of 165 stocks. Click here to see RMD’s complete POWR Ratings.</p><h2>Growth Stocks: Zoetis (ZTS)</h2><p>Zoetis was spun off from Pfizer (NYSE:PFE) in 2013 and is now the leading manufacturer and producer of animal health products including medicines, vaccines, and diagnostic products. Since its debut, the stock is up more than six-fold.</p><p>One major factor in Zoeitis’ growth is that pet ownership is on the rise. Spending on pets is also rising. These trends have been in place for decades and are likely to persist, creating a positive tailwind for animal health companies like ZTS. Additionally, more people are choosing to buy health insurance for their pets, as well.</p><p>The weakness in growth stocks has led to ZTS’ price pulling back by 30%. However, its recent earnings report shows that the company continues to have strong momentum. The company reported an 11% increase in revenue and 14% increase in earnings. For the full year, analysts forecast 16% revenue growth and 21% EPS growth.</p><p>Given these factors, it is not surprising that ZTS has a B rating, which equates to a Buy in our proprietary rating system. B-rated stocks have posted an average annual performance of 21.1% which compares favorably to the S&amp;P 500’s average gain of 8%.</p><p>In terms of component grades, ZTS has an A for Quality and a B for Stability. ZTS is one of the leading companies in a growing sector. It also is returning cash to shareholders via its dividend and through share buybacks. Click here to get more information about ZTS’ POWR Ratings.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks With More Than 50% Upside Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks With More Than 50% Upside Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-26 07:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/02/3-beaten-down-growth-stocks-with-more-than-50-upside-potential/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Following the stock market bottom in Mar. 2020, growth stocks dominated the list of best-performing stocks for the first year of the new bull market. Since then, growth stocks have been mired in a ...</p>\n\n<a href=\"https://investorplace.com/2022/02/3-beaten-down-growth-stocks-with-more-than-50-upside-potential/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZTS":"Zoetis Inc.","VEEV":"Veeva Systems Inc.","RMD":"瑞思迈"},"source_url":"https://investorplace.com/2022/02/3-beaten-down-growth-stocks-with-more-than-50-upside-potential/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191113671","content_text":"Following the stock market bottom in Mar. 2020, growth stocks dominated the list of best-performing stocks for the first year of the new bull market. Since then, growth stocks have been mired in a brutal bear market. There is no better example of this than Cathie Wood’s Ark Innovation ETF (NYSEARCA:ARKK), which had a 391% gain from Mar. 2020 to its high in Feb. 2021. Since then, ARKK has given back most of these gains and is down 60% from these lofty levels.The major factor behind this sharp decline is increasing inflationary pressures, resulting in expectations that the U.S. Federal Reserve will hike rates seven times this year. Rising inflation and interest rates are bearish for growth stocks because it makes their future cash flows less valuable. However, we also know that oversold markets also create an opportunity to buy high-quality stocks at a discount.The key is to look for companies whose earnings momentum and growth are unaffected by changes in economic or monetary conditions. Therefore, investors should consider the following 3 high-quality growth stocks:Veeva Systems (NYSE:VEEV)Resmed, Inc. (NYSE:RMD)Zoetis (NYSE:ZTS)Growth Stocks: Veeva Systems (VEEV)Veeva Systems is a cloud computing and enterprise software company for the healthcare, pharmaceutical, and life sciences industries. It provides software solutions for the unique needs of companies in these industries, from meeting regulatory standards to conducting clinical trials to managing operations.Thus, it is positioned at the intersection of two booming trends — healthcare and cloud computing — which show no signs of exhaustion. These industries have produced some of the biggest stock market winners in recent history.The healthcare sector’s growth is fueled by demographics due to an aging population in developed countries globally, increased government spending, and the constant stream of innovations that lead to new treatments. Healthcare spending as a share of gross domestic product has risen to 18% in 2020 from under 12% in 1990.Veeva combines the growth and high margins of a cloud computing company with the attractive economics of the healthcare industry that has high switching costs and wide moats, leading to high rates of recurring revenue.These positives are reflected in Veeva’s last earnings report which shows a 26% increase in revenue and a 28% jump in operating income. Next quarter, analysts expect 13% earnings growth. This combination of earnings growth and stock price deflation has resulted in valuations becoming quite attractive, especially considering that it has profit margins that are more than double that of the S&P 500 and expectations of double-digit earnings growth over the next five years.Thus, it is not surprising that VEEV has an overall B rating, which translates to a Buy in our POWR Ratings system. It also has an A for Quality. It is one of the leading stocks in a large total addressable market with only a handful of competitors. Additionally, VEEV has a B for growth. This makes sense given its intersection of two large and growing markets — healthcare and cloud computing. Click here to see more of VEEV’s POWR Ratings, including grades for Value, Momentum, and Stability.Resmed, Inc. (RMD)RMD develops, manufactures, distributes, and markets medical devices and software applications for the healthcare market. The company operates in two segments: Sleep and Respiratory Care, and Software as a Service.RMD provides treatments for issues like sleep apnea with its CPAP devices and masks, as well as devices for obstructive pulmonary disease, neuromuscular disease, and other respiratory-related conditions. Unfortunately, due to rising rates of chronic health issues like diabetes and obesity, the demand for RMD’s products is only growing.This makes RMD a high-quality growth stock as its long-term prospects are disconnected from short-term issues like economic growth rates or monetary policy. Instead, RMD is serving a growing market with products that are essential for improving quality of life. Due to their nature, these products also have high margins and rates of recurring revenue.We can see this momentum in its recent earnings report, which showed revenues increasing by 12% and net income increasing by 5%. Next year, analysts forecast revenue growth and earnings per share (EPS) growth of 17% and 15%, respectively.RMD is also a standout in terms of the POWR Ratings with an overall B rating, translating to a Buy. The POWR Ratings assess stocks by 118 distinct factors, each with its own weighting.RMD has strong ratings across the board, including a B grade for Growth as analysts are forecasting double-digit revenue growth over the next decade. Within the Medical – Devices & Equipment industry, RMD is ranked #33 out of 165 stocks. Click here to see RMD’s complete POWR Ratings.Growth Stocks: Zoetis (ZTS)Zoetis was spun off from Pfizer (NYSE:PFE) in 2013 and is now the leading manufacturer and producer of animal health products including medicines, vaccines, and diagnostic products. Since its debut, the stock is up more than six-fold.One major factor in Zoeitis’ growth is that pet ownership is on the rise. Spending on pets is also rising. These trends have been in place for decades and are likely to persist, creating a positive tailwind for animal health companies like ZTS. Additionally, more people are choosing to buy health insurance for their pets, as well.The weakness in growth stocks has led to ZTS’ price pulling back by 30%. However, its recent earnings report shows that the company continues to have strong momentum. The company reported an 11% increase in revenue and 14% increase in earnings. For the full year, analysts forecast 16% revenue growth and 21% EPS growth.Given these factors, it is not surprising that ZTS has a B rating, which equates to a Buy in our proprietary rating system. B-rated stocks have posted an average annual performance of 21.1% which compares favorably to the S&P 500’s average gain of 8%.In terms of component grades, ZTS has an A for Quality and a B for Stability. ZTS is one of the leading companies in a growing sector. It also is returning cash to shareholders via its dividend and through share buybacks. Click here to get more information about ZTS’ POWR Ratings.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":636210538,"gmtCreate":1645869153331,"gmtModify":1645869153608,"author":{"id":"3559357742503712","authorId":"3559357742503712","name":"生肉麵加豬油渣","avatar":"https://static.tigerbbs.com/797772e5857b1091ed85d4b17fe6201b","vip":1,"crmLevel":6,"crmLevelSwitch":1},"htmlText":"abundance e of beaten down stocks...&nbsp;","listText":"abundance e of beaten down stocks...&nbsp;","text":"abundance e of beaten down stocks...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/636210538","repostId":1191113671,"repostType":4,"repost":{"id":"1191113671","pubTimestamp":1645832617,"share":"https://www.laohu8.com/m/news/1191113671?lang=&edition=full","pubTime":"2022-02-26 07:43","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks With More Than 50% Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1191113671","media":"investorplace","summary":"Following the stock market bottom in Mar. 2020, growth stocks dominated the list of best-performing ","content":"<html><head></head><body><p>Following the stock market bottom in Mar. 2020, growth stocks dominated the list of best-performing stocks for the first year of the new bull market. Since then, growth stocks have been mired in a brutal bear market. There is no better example of this than Cathie Wood’s Ark Innovation ETF (NYSEARCA:ARKK), which had a 391% gain from Mar. 2020 to its high in Feb. 2021. Since then, ARKK has given back most of these gains and is down 60% from these lofty levels.</p><p>The major factor behind this sharp decline is increasing inflationary pressures, resulting in expectations that the U.S. Federal Reserve will hike rates seven times this year. Rising inflation and interest rates are bearish for growth stocks because it makes their future cash flows less valuable. However, we also know that oversold markets also create an opportunity to buy high-quality stocks at a discount.</p><p>The key is to look for companies whose earnings momentum and growth are unaffected by changes in economic or monetary conditions. Therefore, investors should consider the following 3 high-quality growth stocks:</p><p>Veeva Systems (NYSE:VEEV)</p><p>Resmed, Inc. (NYSE:RMD)</p><p>Zoetis (NYSE:ZTS)</p><h2>Growth Stocks: Veeva Systems (VEEV)</h2><p>Veeva Systems is a cloud computing and enterprise software company for the healthcare, pharmaceutical, and life sciences industries. It provides software solutions for the unique needs of companies in these industries, from meeting regulatory standards to conducting clinical trials to managing operations.</p><p>Thus, it is positioned at the intersection of two booming trends — healthcare and cloud computing — which show no signs of exhaustion. These industries have produced some of the biggest stock market winners in recent history.</p><p>The healthcare sector’s growth is fueled by demographics due to an aging population in developed countries globally, increased government spending, and the constant stream of innovations that lead to new treatments. Healthcare spending as a share of gross domestic product has risen to 18% in 2020 from under 12% in 1990.</p><p>Veeva combines the growth and high margins of a cloud computing company with the attractive economics of the healthcare industry that has high switching costs and wide moats, leading to high rates of recurring revenue.</p><p>These positives are reflected in Veeva’s last earnings report which shows a 26% increase in revenue and a 28% jump in operating income. Next quarter, analysts expect 13% earnings growth. This combination of earnings growth and stock price deflation has resulted in valuations becoming quite attractive, especially considering that it has profit margins that are more than double that of the S&amp;P 500 and expectations of double-digit earnings growth over the next five years.</p><p>Thus, it is not surprising that VEEV has an overall B rating, which translates to a Buy in our POWR Ratings system. It also has an A for Quality. It is one of the leading stocks in a large total addressable market with only a handful of competitors. Additionally, VEEV has a B for growth. This makes sense given its intersection of two large and growing markets — healthcare and cloud computing. Click here to see more of VEEV’s POWR Ratings, including grades for Value, Momentum, and Stability.</p><h2>Resmed, Inc. (RMD)</h2><p>RMD develops, manufactures, distributes, and markets medical devices and software applications for the healthcare market. The company operates in two segments: Sleep and Respiratory Care, and Software as a Service.</p><p>RMD provides treatments for issues like sleep apnea with its CPAP devices and masks, as well as devices for obstructive pulmonary disease, neuromuscular disease, and other respiratory-related conditions. Unfortunately, due to rising rates of chronic health issues like diabetes and obesity, the demand for RMD’s products is only growing.</p><p>This makes RMD a high-quality growth stock as its long-term prospects are disconnected from short-term issues like economic growth rates or monetary policy. Instead, RMD is serving a growing market with products that are essential for improving quality of life. Due to their nature, these products also have high margins and rates of recurring revenue.</p><p>We can see this momentum in its recent earnings report, which showed revenues increasing by 12% and net income increasing by 5%. Next year, analysts forecast revenue growth and earnings per share (EPS) growth of 17% and 15%, respectively.</p><p>RMD is also a standout in terms of the POWR Ratings with an overall B rating, translating to a Buy. The POWR Ratings assess stocks by 118 distinct factors, each with its own weighting.</p><p>RMD has strong ratings across the board, including a B grade for Growth as analysts are forecasting double-digit revenue growth over the next decade. Within the Medical – Devices &amp; Equipment industry, RMD is ranked #33 out of 165 stocks. Click here to see RMD’s complete POWR Ratings.</p><h2>Growth Stocks: Zoetis (ZTS)</h2><p>Zoetis was spun off from Pfizer (NYSE:PFE) in 2013 and is now the leading manufacturer and producer of animal health products including medicines, vaccines, and diagnostic products. Since its debut, the stock is up more than six-fold.</p><p>One major factor in Zoeitis’ growth is that pet ownership is on the rise. Spending on pets is also rising. These trends have been in place for decades and are likely to persist, creating a positive tailwind for animal health companies like ZTS. Additionally, more people are choosing to buy health insurance for their pets, as well.</p><p>The weakness in growth stocks has led to ZTS’ price pulling back by 30%. However, its recent earnings report shows that the company continues to have strong momentum. The company reported an 11% increase in revenue and 14% increase in earnings. For the full year, analysts forecast 16% revenue growth and 21% EPS growth.</p><p>Given these factors, it is not surprising that ZTS has a B rating, which equates to a Buy in our proprietary rating system. B-rated stocks have posted an average annual performance of 21.1% which compares favorably to the S&amp;P 500’s average gain of 8%.</p><p>In terms of component grades, ZTS has an A for Quality and a B for Stability. ZTS is one of the leading companies in a growing sector. It also is returning cash to shareholders via its dividend and through share buybacks. Click here to get more information about ZTS’ POWR Ratings.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks With More Than 50% Upside Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks With More Than 50% Upside Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-26 07:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/02/3-beaten-down-growth-stocks-with-more-than-50-upside-potential/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Following the stock market bottom in Mar. 2020, growth stocks dominated the list of best-performing stocks for the first year of the new bull market. Since then, growth stocks have been mired in a ...</p>\n\n<a href=\"https://investorplace.com/2022/02/3-beaten-down-growth-stocks-with-more-than-50-upside-potential/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZTS":"Zoetis Inc.","VEEV":"Veeva Systems Inc.","RMD":"瑞思迈"},"source_url":"https://investorplace.com/2022/02/3-beaten-down-growth-stocks-with-more-than-50-upside-potential/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191113671","content_text":"Following the stock market bottom in Mar. 2020, growth stocks dominated the list of best-performing stocks for the first year of the new bull market. Since then, growth stocks have been mired in a brutal bear market. There is no better example of this than Cathie Wood’s Ark Innovation ETF (NYSEARCA:ARKK), which had a 391% gain from Mar. 2020 to its high in Feb. 2021. Since then, ARKK has given back most of these gains and is down 60% from these lofty levels.The major factor behind this sharp decline is increasing inflationary pressures, resulting in expectations that the U.S. Federal Reserve will hike rates seven times this year. Rising inflation and interest rates are bearish for growth stocks because it makes their future cash flows less valuable. However, we also know that oversold markets also create an opportunity to buy high-quality stocks at a discount.The key is to look for companies whose earnings momentum and growth are unaffected by changes in economic or monetary conditions. Therefore, investors should consider the following 3 high-quality growth stocks:Veeva Systems (NYSE:VEEV)Resmed, Inc. (NYSE:RMD)Zoetis (NYSE:ZTS)Growth Stocks: Veeva Systems (VEEV)Veeva Systems is a cloud computing and enterprise software company for the healthcare, pharmaceutical, and life sciences industries. It provides software solutions for the unique needs of companies in these industries, from meeting regulatory standards to conducting clinical trials to managing operations.Thus, it is positioned at the intersection of two booming trends — healthcare and cloud computing — which show no signs of exhaustion. These industries have produced some of the biggest stock market winners in recent history.The healthcare sector’s growth is fueled by demographics due to an aging population in developed countries globally, increased government spending, and the constant stream of innovations that lead to new treatments. Healthcare spending as a share of gross domestic product has risen to 18% in 2020 from under 12% in 1990.Veeva combines the growth and high margins of a cloud computing company with the attractive economics of the healthcare industry that has high switching costs and wide moats, leading to high rates of recurring revenue.These positives are reflected in Veeva’s last earnings report which shows a 26% increase in revenue and a 28% jump in operating income. Next quarter, analysts expect 13% earnings growth. This combination of earnings growth and stock price deflation has resulted in valuations becoming quite attractive, especially considering that it has profit margins that are more than double that of the S&P 500 and expectations of double-digit earnings growth over the next five years.Thus, it is not surprising that VEEV has an overall B rating, which translates to a Buy in our POWR Ratings system. It also has an A for Quality. It is one of the leading stocks in a large total addressable market with only a handful of competitors. Additionally, VEEV has a B for growth. This makes sense given its intersection of two large and growing markets — healthcare and cloud computing. Click here to see more of VEEV’s POWR Ratings, including grades for Value, Momentum, and Stability.Resmed, Inc. (RMD)RMD develops, manufactures, distributes, and markets medical devices and software applications for the healthcare market. The company operates in two segments: Sleep and Respiratory Care, and Software as a Service.RMD provides treatments for issues like sleep apnea with its CPAP devices and masks, as well as devices for obstructive pulmonary disease, neuromuscular disease, and other respiratory-related conditions. Unfortunately, due to rising rates of chronic health issues like diabetes and obesity, the demand for RMD’s products is only growing.This makes RMD a high-quality growth stock as its long-term prospects are disconnected from short-term issues like economic growth rates or monetary policy. Instead, RMD is serving a growing market with products that are essential for improving quality of life. Due to their nature, these products also have high margins and rates of recurring revenue.We can see this momentum in its recent earnings report, which showed revenues increasing by 12% and net income increasing by 5%. Next year, analysts forecast revenue growth and earnings per share (EPS) growth of 17% and 15%, respectively.RMD is also a standout in terms of the POWR Ratings with an overall B rating, translating to a Buy. The POWR Ratings assess stocks by 118 distinct factors, each with its own weighting.RMD has strong ratings across the board, including a B grade for Growth as analysts are forecasting double-digit revenue growth over the next decade. Within the Medical – Devices & Equipment industry, RMD is ranked #33 out of 165 stocks. Click here to see RMD’s complete POWR Ratings.Growth Stocks: Zoetis (ZTS)Zoetis was spun off from Pfizer (NYSE:PFE) in 2013 and is now the leading manufacturer and producer of animal health products including medicines, vaccines, and diagnostic products. Since its debut, the stock is up more than six-fold.One major factor in Zoeitis’ growth is that pet ownership is on the rise. Spending on pets is also rising. These trends have been in place for decades and are likely to persist, creating a positive tailwind for animal health companies like ZTS. Additionally, more people are choosing to buy health insurance for their pets, as well.The weakness in growth stocks has led to ZTS’ price pulling back by 30%. However, its recent earnings report shows that the company continues to have strong momentum. The company reported an 11% increase in revenue and 14% increase in earnings. For the full year, analysts forecast 16% revenue growth and 21% EPS growth.Given these factors, it is not surprising that ZTS has a B rating, which equates to a Buy in our proprietary rating system. B-rated stocks have posted an average annual performance of 21.1% which compares favorably to the S&P 500’s average gain of 8%.In terms of component grades, ZTS has an A for Quality and a B for Stability. ZTS is one of the leading companies in a growing sector. It also is returning cash to shareholders via its dividend and through share buybacks. Click here to get more information about ZTS’ POWR Ratings.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":42,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}